Dual inhibition of EGFR and PI3Kinase signaling in EGFR amplified triple negative breast cancer cells induces apoptosis and reduces tumor growth.

ABSTRACT:

Background

Epidermal Growth Factor Receptor (EGFR) family signaling is commonly dysregulated in cancer by amplification or activating mutations. We investigated the incidence of EGFR amplification with or without PI3Kinase pathway mutations in breast cancer and whether patients with genetic abnormalities in both pathways can be targeted by dual EGFR/PI3K inhibition.

Methods

EGFR amplification and PI3K pathway mutations were studied through data sets from cBioPortal and Caris. We used the triple negative breast cancer (TNBC) cell lines BT20 (amplified EGFR, PIK3CA activating mutation), MDA-MB-468 (amplified EGFR, PTEN deletion), and MDA-MB-231 (no amplification of EGFR or PI3K pathway mutations). EGFR amplification was determined by immunoblot and fluorescent in situ hybridiz

SUBMITTER: Wisniewski DJ 

PROVIDER: S-EPMC12157506 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature